Adipogenic differentiation

Adipogenic differentiation, commonly referred to as adipogenesis, is the complex biological process by which undifferentiated precursor cells, such as mesenchymal stem cells or preadipocytes, commit to and develop into mature, lipid-storing adipocytes [1, 3, 7]. This transformation is orchestrated by a highly coordinated transcriptional cascade, with the nuclear receptor peroxisome proliferator-activated receptor gamma (PPARG) acting as the master regulator, supported by members of the CCAAT/enhancer-binding protein (C/EBP) family [2, 6, 11]. Adipogenesis plays a critical role in maintaining energy balance and systemic insulin sensitivity; however, its pathological expansion or dysfunction is central to the development of obesity and type 2 diabetes [3, 4, 12]. Although 'Adipogenic differentiation' is a process rather than a single molecule, it is frequently treated as a therapeutic target in drug discovery efforts aimed at modulating fat accumulation or improving metabolic health [1, 5]. Pharmacological modulators of this process include thiazolidinediones, which are PPARG agonists, as well as various chemical components like dexamethasone and phosphodiesterase inhibitors used in experimental 'adipogenic cocktails' [2, 7, 9]. Research into this process is also exploring the role of exosomes and miRNAs as potential therapeutic avenues for obesity and tissue engineering [8, 12].

Other names

AdipogenesisPreadipocyte differentiationFat cell differentiation

The modulation of adipogenic differentiation is achieved through several pathways: the activation of the master transcription factor PPAR-gamma (PPARG) by agonists like thiazolidinediones; the activation of glucocorticoid receptors (GR) by dexamethasone; the inhibition of phosphodiesterases (PDE) by IBMX to increase intracellular cAMP levels; and the stimulation of insulin signaling through AKT/mTOR pathways [1, 2, 4, 7].